# Candesartan's Effects on Alzheimer's Disease And Related Biomarkers

> **NCT02646982** · PHASE2 · COMPLETED · sponsor: **Emory University** · enrollment: 77 (actual)

## Conditions studied

- Mild Cognitive Impairment

## Interventions

- **DRUG:** Placebo
- **DRUG:** Candesartan

## Key facts

- **NCT ID:** NCT02646982
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-30
- **Primary completion:** 2020-08-17
- **Final completion:** 2020-08-17
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2022-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02646982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02646982, "Candesartan's Effects on Alzheimer's Disease And Related Biomarkers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02646982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*